View in EDS

Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.

Saved in:
Bibliographic Details
Title: Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
Authors: Li, Guiling1 (AUTHOR), Li, Xiaofan1,2 (AUTHOR), Yin, Rutie3 (AUTHOR), Feng, Mei4 (AUTHOR), Zuo, Jing5 (AUTHOR), Wei, Shuqing6 (AUTHOR), Kang, Shan7 (AUTHOR), Sun, Hongmei8 (AUTHOR), Li, Xiumin9 (AUTHOR), Wang, Yili10 (AUTHOR), Zhang, Yunyan11 (AUTHOR), Sun, Li12 (AUTHOR), Lin, Daren13 (AUTHOR), Ruan, Xiaohong13 (AUTHOR), Zhu, Zhitu14 (AUTHOR), Jiang, Kui15 (AUTHOR), Liu, Hu16 (AUTHOR), Wang, Wei17 (AUTHOR), Hao, Deshun18 (AUTHOR), Chen, Ying18 (AUTHOR)
Source: Gynecologic Oncology. Dec2024, Vol. 191, p165-171. 7p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/j.ygyno.2024.10.001